img

Markt für bioähnliche monoklonale Antikörper (Mabs) nach Produkttyp (Rituximab-Biosimilars, Infliximab-Biosimilars, Trastuzumab-Biosimilars, Adalimumab-Biosimilars, Bevacizumab-Biosimilars), Anwendung (Onkologie, Autoimmunerkrankungen, Infektionskrankheiten), Endverbraucher (Krankenhäuser, Kliniken, Forschungsinstitute) und Region für 2024–2031

Published on: 2024-10-01 | No of Pages : 220 | Industry : latest trending Report

Publisher : MIR | Format : PDF&Excel

Select User License

$2890 Single Licence
$4335 Enterprise Licence
$5780 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@marketinsightsresearch.com

Within 24 to 48 hrs.

You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email